• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤抑制因子PP2A在细胞转化中调控的多种途径。

Multiple pathways regulated by the tumor suppressor PP2A in transformation.

作者信息

Westermarck Jukka, Hahn William C

机构信息

Institute of Medical Technology, University of Tampere and Tampere University Hospital, 33520 Tampere, Finland.

出版信息

Trends Mol Med. 2008 Apr;14(4):152-60. doi: 10.1016/j.molmed.2008.02.001. Epub 2008 Mar 10.

DOI:10.1016/j.molmed.2008.02.001
PMID:18329957
Abstract

Reversible protein phosphorylation plays a central role in regulating intracellular signaling. Dysregulation of the mechanisms that regulate phosphorylation plays a direct role in cancer initiation and maintenance. Although abundant evidence supports the role of kinase oncogenes in cancer development, recent work has illuminated the role of specific protein phosphatases in malignant transformation. Protein phosphatase 2A (PP2A) is the major serine-threonine phosphatase in mammalian cells. Inactivation of PP2A by viral oncoproteins, mutation of specific subunits or overexpression of endogenous inhibitors contributes to cell transformation by regulating specific phosphorylation events. Here, we review recent progress in our understanding of how PP2A regulates mitogenic signaling pathways in cancer pathogenesis and how PP2A activity is modulated in human cancers.

摘要

可逆性蛋白质磷酸化在调节细胞内信号传导中起核心作用。调节磷酸化的机制失调在癌症的发生和维持中起直接作用。尽管有大量证据支持激酶癌基因在癌症发展中的作用,但最近的研究揭示了特定蛋白磷酸酶在恶性转化中的作用。蛋白磷酸酶2A(PP2A)是哺乳动物细胞中的主要丝氨酸 - 苏氨酸磷酸酶。病毒癌蛋白使PP2A失活、特定亚基的突变或内源性抑制剂的过表达通过调节特定的磷酸化事件促进细胞转化。在此,我们综述了我们对PP2A如何在癌症发病机制中调节有丝分裂信号通路以及PP2A活性在人类癌症中如何被调节的最新认识进展。

相似文献

1
Multiple pathways regulated by the tumor suppressor PP2A in transformation.肿瘤抑制因子PP2A在细胞转化中调控的多种途径。
Trends Mol Med. 2008 Apr;14(4):152-60. doi: 10.1016/j.molmed.2008.02.001. Epub 2008 Mar 10.
2
Involvement of PP2A in viral and cellular transformation.蛋白磷酸酶2A在病毒及细胞转化中的作用。
Oncogene. 2005 Nov 21;24(52):7746-55. doi: 10.1038/sj.onc.1209038.
3
SV40 small T antigen and PP2A phosphatase in cell transformation.细胞转化中的SV40小T抗原与PP2A磷酸酶
Cancer Metastasis Rev. 2008 Jun;27(2):137-46. doi: 10.1007/s10555-008-9116-0.
4
[Protein phosphatase 2A: its structure, function and activity regulation].[蛋白磷酸酶2A:其结构、功能及活性调节]
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Feb;35(2):105-12.
5
C3G mediated suppression of malignant transformation involves activation of PP2A phosphatases at the subcortical actin cytoskeleton.C3G介导的恶性转化抑制涉及皮层下肌动蛋白细胞骨架处PP2A磷酸酶的激活。
Exp Cell Res. 2007 Nov 1;313(18):3881-91. doi: 10.1016/j.yexcr.2007.07.036. Epub 2007 Aug 14.
6
The use of okadaic acid to elucidate the intracellular role(s) of protein phosphatase 2A: lessons from the mast cell model system.利用冈田酸阐明蛋白磷酸酶2A的细胞内作用:来自肥大细胞模型系统的经验教训。
Int Immunopharmacol. 2005 Sep;5(10):1507-18. doi: 10.1016/j.intimp.2005.05.007.
7
The role of PP2A A subunits in tumor suppression.蛋白磷酸酶2A A亚基在肿瘤抑制中的作用。
Cell Adh Migr. 2007 Jul-Sep;1(3):140-1. doi: 10.4161/cam.1.3.4986. Epub 2007 Jul 5.
8
Protein phosphatase 2A regulatory subunits and cancer.蛋白磷酸酶2A调节亚基与癌症
Biochim Biophys Acta. 2009 Jan;1795(1):1-15. doi: 10.1016/j.bbcan.2008.05.005. Epub 2008 Jun 3.
9
Tyrosine phosphorylation of PP2A is regulated by HER-2 signalling and correlates with breast cancer progression.PP2A的酪氨酸磷酸化受HER-2信号传导调节,并与乳腺癌进展相关。
Int J Oncol. 2009 May;34(5):1291-301.
10
Regulation by tumour antigens defines a role for PP2A in signal transduction.肿瘤抗原介导的调控作用明确了PP2A在信号转导中的作用。
Semin Cancer Biol. 1995 Aug;6(4):229-37. doi: 10.1006/scbi.1995.0030.

引用本文的文献

1
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity.HMGA2与蛋白质亮氨酸甲基化驱动胰腺癌谱系可塑性。
Nat Commun. 2025 May 26;16(1):4866. doi: 10.1038/s41467-025-60129-1.
2
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology.靶向MYC:肿瘤学中的多维调控与治疗策略
Genes Dis. 2024 Sep 16;12(4):101435. doi: 10.1016/j.gendis.2024.101435. eCollection 2025 Jul.
3
TTC36 promotes proliferation and drug resistance in hepatocellular carcinoma cells by inhibiting c-Myc degradation.
TTC36通过抑制c-Myc降解促进肝癌细胞的增殖和耐药性。
Cell Death Dis. 2025 Apr 24;16(1):332. doi: 10.1038/s41419-025-07663-4.
4
Germline mutations in PPP2R1B in patients with a personal and family history of cancer.有个人和家族癌症病史患者中PPP2R1B的种系突变。
JCI Insight. 2025 Apr 3;10(9). doi: 10.1172/jci.insight.186288. eCollection 2025 May 8.
5
PP2A activation overcomes leptomeningeal dissemination in group 3 medulloblastoma.蛋白磷酸酶2A(PP2A)的激活克服了3组髓母细胞瘤的软脑膜播散。
J Biol Chem. 2024 Nov;300(11):107892. doi: 10.1016/j.jbc.2024.107892. Epub 2024 Oct 16.
6
BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription.BRG1 通过破坏 PPP2R1A 转录促进 B 细胞急性淋巴细胞白血病的进展。
Cell Death Dis. 2024 Aug 26;15(8):621. doi: 10.1038/s41419-024-06996-w.
7
TIPRL Regulates Stemness and Survival in Lung Cancer Stem Cells through CaMKK2-CaMK4-CREB Feedback Loop Activation.TIPRL 通过 CaMKK2-CaMK4-CREB 反馈环激活调控肺癌干细胞干性和存活。
Adv Sci (Weinh). 2024 Sep;11(36):e2406309. doi: 10.1002/advs.202406309. Epub 2024 Jul 30.
8
ent-8(14),15-Pimaradiene-2β,19-diol, a diterpene from Aleuritopteris albofusca, inhibits growth and induces protective autophagy in hepatocellular carcinoma cells.来源于白桫椤的二萜 ent-8(14),15- 新松香二烯-2β,19-二醇抑制肝癌细胞生长并诱导保护性自噬。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6867-6878. doi: 10.1007/s00210-024-03048-0. Epub 2024 Apr 3.
9
PP2A Affects Angiogenesis via Its Interaction with a Novel Phosphorylation Site of TSP1.PP2A 通过与 TSP1 的新磷酸化位点相互作用影响血管生成。
Int J Mol Sci. 2024 Feb 3;25(3):1844. doi: 10.3390/ijms25031844.
10
Cellular Impacts of Striatins and the STRIPAK Complex and Their Roles in the Development and Metastasis in Clinical Cancers (Review).条纹蛋白和STRIPAK复合体的细胞影响及其在临床癌症发生和转移中的作用(综述)
Cancers (Basel). 2023 Dec 22;16(1):76. doi: 10.3390/cancers16010076.